At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
Ofatumumab +1 moredrug
Likely dose
Ofatumumab 2000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
In Brief
A Phase 2 clinical trial evaluating Ofatumumab and Lenalidomide for Chronic Lymphocytic Leukemia. Completed, enrolled 21 participants across 2 sites.
Detailed Summary
The purpose of this research is to evaluate the safety and effectiveness of the drugs lenalidomide and ofatumumab in the treatment of chronic lymphocytic leukemia (CLL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Lymphocytic Leukemia
CountriesUnited States
CollaboratorsGlaxoSmithKline, Celgene Corporation
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedMay 2010
Primary CompletionMay 2013
Study CompletionJun 2013
TodayJul 2026
First PostedMay 14, 2010
Enrollment StartMay 1, 2010
Primary CompletionMay 1, 2013
Study CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 16.1 years ago
Interventions
Ofatumumabdrug
* Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1 for up to 6 cycles (28 day cycles) * Treatment to be administered for up to 6 cycles
Lenalidomidedrug
-Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28 for up to 6 cycles (28 day cycles)